跳至主要内容
临床试验/2023-503525-19-00
2023-503525-19-00已完成1 期

Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)

Akamis Bio Limited2 个研究点 分布在 2 个国家目标入组 85 人开始时间: 2023年5月23日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
85
试验地点
2

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Andrew Fox

Scientific

Akamis Bio Limited

研究点 (2)

Loading locations...

相似试验

已完成
2 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer
2024-516004-42-01Bristol Myers Squibb International Corporation143
已完成
3 期
A phase III study of nivolumab(ONO-4538-66/CA2099TM )
jRCT2080223754ONO PHARMACEUTICAL CO.,LTD.1,046
进行中(未招募)
1 期
ivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade gliomaewly diagnosed High-Grade Gliomas (HGG)MedDRA version: 20.0 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10018338 Term: Glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-002688-24-FRGustave Roussy40
进行中(未招募)
1 期
Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-003334-25-DEniversity of Cologne90
已完成
1 期
A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV MelanomaMelanoma
ACTRN12617000772347Peter MacCallum Cancer Centre52